IP Library › Granted Patent US 12,371,505
Granted Patent B2
US 12,371,505 · App. 17/853,794 · Granted Jul 29, 2025

Anti-BCMA heavy chain-only antibodies

Inventors: Shelley Force Aldred (Hayward, CA); Nathan Trinklein (Redwood City, CA); Katherine E. Harris (Fremont, CA); Kevin Dang (Thousand Oaks, CA); Wim van Schooten (Sunnyvale, CA)
Assignee: TeneoBio, Inc.
C07K16/2878C07K2317/21C07K2317/31C07K2317/565C07K2317/732C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,505
App. No.
17/853,794
Granted
Jul 29, 2025
Kind
B2
Abstract

Anti-BCMA heavy chain-only antibodies(HCAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.

Claims (12)

1. A heavy chain-only antibody binding to human B-Cell Maturation Antigen (BCMA) comprising a heavy chain variable region comprising:

a CDR1 sequence comprising SEQ ID NO: 3, a CDR2 sequence comprising SEQ ID NO: 7, and

a CDR3 sequence comprising SEQ ID NO: 19.

2. A pharmaceutical composition comprising the heavy chain-only antibody of claim 1 .

3. The heavy chain-only antibody of claim 1 , wherein the heavy chain variable region has at least 95% sequence identity to SEQ ID NO: 48.

4. The heavy chain-only antibody of claim 1 , wherein the heavy chain variable region comprises SEQ ID NO: 48.

5. The heavy chain-only antibody of claim 1 , further comprising a heavy chain constant region sequence in the absence of a CH1 sequence.

6. The heavy chain-only antibody of claim 1 , which is in a CAR-T format.

7. The heavy chain-only antibody of claim 1 , which is present in a CAR-transduced T-cell.

8. A polynucleotide encoding the antibody of claim 1 .

9. A vector comprising the polynucleotide of claim 8 .

10. A cell comprising the vector of claim 9 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2024
From: FORCE ALDRED, SHELLEY; TRINKLEIN, NATHAN; HARRIS, KATHERINE; DANG, KEVIN; VAN SCHOOTEN, WIM
To: TENEOBIO, INC.
Reel/Frame 066499/0900 →
Continuity (3)
Continuation 16472173
Provisional Application 62437588 · Dec 21, 2016
Related Publication 20230045100A1 · Feb 9, 2023
References Cited (400)
US 4275149A · Litman et al. · 1981 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5500360A · Ahlquist et al. · 1996 [cited by applicant]
US 5500362A · Robinson et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5585097A · Bolt et al. · 1996 [cited by applicant]
US 5595097A · Anderson · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5929212A · Jolliffe et al. · 1999 [cited by applicant]
US 5968509A · Gorman et al. · 1999 [cited by applicant]
US 6037453A · Jardieu et al. · 2000 [cited by applicant]
US 6407213B1 · Carter et al. · 2002 [cited by applicant]
US 6548640B1 · Winter · 2003 [cited by applicant]
US 6706265B1 · Bolt et al. · 2004 [cited by applicant]
US 6750325B1 · Jolliffe et al. · 2004 [cited by applicant]
US 6982321B2 · Winter · 2006 [cited by applicant]
US 7083785B2 · Browning et al. · 2006 [cited by applicant]
US 7262276B2 · Huang et al. · 2007 [cited by applicant]
US 7381803B1 · Weiner et al. · 2008 [cited by applicant]
US 7541513B2 · Bruggeman et al. · 2009 [cited by applicant]
US 7635472B2 · Kufer et al. · 2009 [cited by applicant]
US 7691804B2 · Jeffrey et al. · 2010 [cited by applicant]
US 7728114B2 · Mach et al. · 2010 [cited by applicant]
US 7862813B2 · Bjork et al. · 2011 [cited by applicant]
US 8106163B2 · Heusser et al. · 2012 [cited by applicant]
US 8207303B2 · Cardarelli et al. · 2012 [cited by applicant]
US 8236308B2 · Kischel et al. · 2012 [cited by applicant]
US 8367888B2 · Bruggemann et al. · 2013 [cited by applicant]
US 8703485B2 · Buelow · 2014 [cited by applicant]
US 8883150B2 · Craig et al. · 2014 [cited by applicant]
US 9034324B2 · Kalled et al. · 2015 [cited by applicant]
US 9096651B2 · Igawa et al. · 2015 [cited by applicant]
US 9150664B2 · Kufer et al. · 2015 [cited by applicant]
US 9228016B2 · Wang et al. · 2016 [cited by applicant]
US 9340621B2 · Kufer et al. · 2016 [cited by applicant]
US 9365655B2 · Craig et al. · 2016 [cited by applicant]
US 9587036B2 · Kufer et al. · 2017 [cited by applicant]
US 9598500B2 · Kufer et al. · 2017 [cited by applicant]
US 9650430B2 · Browning et al. · 2017 [cited by applicant]
US 9657102B2 · Smith et al. · 2017 [cited by applicant]
US 9765342B2 · Kochenderfer · 2017 [cited by applicant]
US 10202452B2 · Tan et al. · 2019 [cited by applicant]
US 10465009B2 · Armitage et al. · 2019 [cited by applicant]
US 10465010B2 · Wang et al. · 2019 [cited by applicant]
US 10494416B2 · Browning et al. · 2019 [cited by applicant]
US 10766969B2 · Kufer et al. · 2020 [cited by applicant]
US 10934363B2 · Fan et al. · 2021 [cited by applicant]
US 11072656B2 · Smith et al. · 2021 [cited by applicant]
US 11155621B2 · Smith et al. · 2021 [cited by applicant]
US 11186639B2 · Harris et al. · 2021 [cited by applicant]
US 11384153B2 · Smith et al. · 2022 [cited by applicant]
US 11390681B2 · Harris et al. · 2022 [cited by applicant]
US 11421027B2 · Trinklein et al. · 2022 [cited by applicant]
US 11427642B2 · Trinklein et al. · 2022 [cited by applicant]
US 11434299B2 · Force Aldred et al. · 2022 [cited by applicant]
US 11505606B2 · Trinklein et al. · 2022 [cited by applicant]
US 11613572B2 · Trinklein et al. · 2023 [cited by applicant]
US 11905326B2 · Trinklein et al. · 2024 [cited by applicant]
US 20010024811A1 · Khosla et al. · 2001 [cited by applicant]
US 20010024812A1 · Guegler et al. · 2001 [cited by applicant]
US 20020066516A1 · Cornell · 2002 [cited by applicant]
US 20040229310A1 · Simmons · 2004 [cited by applicant]
US 20050048572A1 · Reilly et al. · 2005 [cited by applicant]
US 20060008548A1 · Tung · 2006 [cited by applicant]
US 20070065437A1 · Elson et al. · 2007 [cited by applicant]
US 20070071675A1 · Wu et al. · 2007 [cited by applicant]
US 20070212733A1 · Martin · 2007 [cited by applicant]
US 20090098134A1 · Buelow · 2009 [cited by applicant]
US 20100122358A1 · Bruggemann et al. · 2010 [cited by applicant]
US 20100150918A1 · Kufer et al. · 2010 [cited by applicant]
US 20110129458A1 · Dolk et al. · 2011 [cited by applicant]
US 20110293619A1 · Kufer et al. · 2011 [cited by applicant]
US 20130101599A1 · Borges et al. · 2013 [cited by applicant]
US 20130129729A1 · Kischel et al. · 2013 [cited by applicant]
US 20130156769A1 · Kufer et al. · 2013 [cited by applicant]
US 20130195888A1 · Wang et al. · 2013 [cited by applicant]
US 20130273055A1 · Borges et al. · 2013 [cited by applicant]
US 20130273066A1 · Gokarn et al. · 2013 [cited by applicant]
US 20130280280A1 · Algate et al. · 2013 [cited by applicant]
US 20140056897A1 · Buelow et al. · 2014 [cited by applicant]
US 20140088295A1 · Smith et al. · 2014 [cited by applicant]
US 20140220021A1 · Shibayama et al. · 2014 [cited by applicant]
US 20150118251A1 · Deslandes · 2015 [cited by applicant]
US 20150266966A1 · Smith et al. · 2015 [cited by applicant]
US 20150337054A1 · Gardner, II et al. · 2015 [cited by applicant]
US 20150368351A1 · Vu et al. · 2015 [cited by applicant]
US 20150376287A1 · Vu et al. · 2015 [cited by applicant]
US 20160046724A1 · Brogdon et al. · 2016 [cited by applicant]
US 20160159894A1 · Hartmann et al. · 2016 [cited by applicant]
US 20160166689A1 · Adler et al. · 2016 [cited by applicant]
US 20160194399A1 · Irving et al. · 2016 [cited by applicant]
US 20160355591A1 · Goldenberg et al. · 2016 [cited by applicant]
US 20170051068A1 · Pillarisetti et al. · 2017 [cited by applicant]
US 20170081411A1 · Engels et al. · 2017 [cited by applicant]
US 20170240612A1 · Bachmann et al. · 2017 [cited by applicant]
US 20190070290A1 · Kischel et al. · 2019 [cited by applicant]
US 20190106504A1 · Wu et al. · 2019 [cited by applicant]
US 20190151448A1 · Abel et al. · 2019 [cited by applicant]
US 20190225671A1 · Van Schooten et al. · 2019 [cited by applicant]
US 20190263904A1 · Trinklein et al. · 2019 [cited by applicant]
US 20190284294A1 · Deslandes et al. · 2019 [cited by applicant]
US 20190352412A1 · Force Aldred et al. · 2019 [cited by applicant]
US 20200048348A1 · Trinklein et al. · 2020 [cited by applicant]
US 20200078399A1 · Fan et al. · 2020 [cited by applicant]
US 20200085839A1 · Sidransky et al. · 2020 [cited by applicant]
US 20200095305A1 · Browning et al. · 2020 [cited by applicant]
US 20200095319A1 · Kufer et al. · 2020 [cited by applicant]
US 20200123269A1 · Fan et al. · 2020 [cited by applicant]
US 20200129617A1 · Brownstein et al. · 2020 [cited by applicant]
US 20200131262A1 · Ehninger · 2020 [cited by applicant]
US 20200138865A1 · Kochenderfer et al. · 2020 [cited by applicant]
US 20200157232A1 · Trinklein et al. · 2020 [cited by applicant]
US 20200181228A1 · Bachmann et al. · 2020 [cited by applicant]
US 20200190205A1 · Adams et al. · 2020 [cited by applicant]
US 20200332000A1 · McAuley et al. · 2020 [cited by applicant]
US 20200339685A1 · Schellenberger et al. · 2020 [cited by applicant]
US 20210047407A1 · Christian et al. · 2021 [cited by applicant]
US 20210095022A1 · Force Aldred et al. · 2021 [cited by applicant]
US 20210139577A1 · Dillon et al. · 2021 [cited by applicant]
US 20210139584A1 · Minella et al. · 2021 [cited by applicant]
US 20210147564A1 · Trinklein et al. · 2021 [cited by applicant]
US 20210163620A1 · Granda et al. · 2021 [cited by applicant]
US 20210284732A1 · Zugmaier et al. · 2021 [cited by applicant]
US 20210332133A1 · Force Aldred et al. · 2021 [cited by applicant]
US 20210340255A1 · Harris et al. · 2021 [cited by applicant]
US 20210341487A1 · Partridge et al. · 2021 [cited by applicant]
US 20210355215A1 · Jorgensen et al. · 2021 [cited by applicant]
US 20210388106A1 · Van Schooten et al. · 2021 [cited by applicant]
US 20210395298A1 · Bondarenko et al. · 2021 [cited by applicant]
US 20210403587A1 · Buelow et al. · 2021 [cited by applicant]
US 20220025047A1 · Trinklein et al. · 2022 [cited by applicant]
US 20220041742A1 · Adams et al. · 2022 [cited by applicant]
US 20220064336A1 · Kufer et al. · 2022 [cited by applicant]
US 20220089729A1 · Harris et al. · 2022 [cited by applicant]
US 20220098324A1 · Weiner et al. · 2022 [cited by applicant]
US 20220137010A1 · Wen · 2022 [cited by applicant]
US 20220144947A1 · Smith et al. · 2022 [cited by applicant]
US 20220195068A1 · Van Schooten et al. · 2022 [cited by applicant]
US 20220251243A1 · Kufer et al. · 2022 [cited by applicant]
US 20220259547A1 · Khurshid · 2022 [cited by applicant]
US 20220306741A1 · Sharma et al. · 2022 [cited by applicant]
US 20220306758A1 · Smith et al. · 2022 [cited by applicant]
US 20220332820A1 · Harris et al. · 2022 [cited by applicant]
US 20220356268A1 · Kufer et al. · 2022 [cited by applicant]
US 20220378908A1 · Zhu et al. · 2022 [cited by applicant]
US 20220389055A1 · Davis et al. · 2022 [cited by applicant]
US 20220396599A1 · Wang et al. · 2022 [cited by applicant]
US 20220403035A1 · Anlahr et al. · 2022 [cited by applicant]
US 20230057602A1 · Burgess et al. · 2023 [cited by applicant]
US 20230060847A1 · Trinklein et al. · 2023 [cited by applicant]
US 20230082151A1 · Trinklein et al. · 2023 [cited by applicant]
US 20230257473A1 · Trinklein et al. · 2023 [cited by applicant]
US 20230272075A1 · Trinklein et al. · 2023 [cited by applicant]
CA 2828347A1 · 2012 [cited by applicant]
CN 1551886A · 2004 [cited by applicant]
CN 1889979A · 2007 [cited by applicant]
CN 101627055A · 2010 [cited by applicant]
CN 101874042 · 2010 [cited by applicant]
CN 102119174A · 2011 [cited by applicant]
CN 1889979B · 2012 [cited by applicant]
CN 103608039A · 2014 [cited by applicant]
CN 103619876A · 2014 [cited by applicant]
CN 104379179A · 2015 [cited by applicant]
CN 104877026 · 2015 [cited by applicant]
CN 104877026A · 2015 [cited by applicant]
CN 104968682A · 2015 [cited by applicant]
CN 105143263A · 2015 [cited by applicant]
CN 105384825A · 2016 [cited by applicant]
CN 105457024 · 2016 [cited by applicant]
CN 105777906A · 2016 [cited by applicant]
CN 106459203A · 2017 [cited by applicant]
CN 106687483A · 2017 [cited by applicant]
CN 103703024B · 2017 [cited by applicant]
CN 104114578B · 2018 [cited by applicant]
CN 101874042B9 · 2019 [cited by applicant]
EA 201591091A1 · 2016 [cited by applicant]
EP 1210425B1 · 2007 [cited by applicant]
EP 1223964B1 · 2007 [cited by applicant]
EP 2762496A1 · 2014 [cited by applicant]
EP 2762497A1 · 2014 [cited by applicant]
EP 2970472A1 · 2016 [cited by applicant]
EP 1806143B1 · 2016 [cited by applicant]
EP 2780374B1 · 2019 [cited by applicant]
EP 2780375B1 · 2019 [cited by applicant]
EP 3611193A1 · 2020 [cited by applicant]
EP 3623385A1 · 2020 [cited by applicant]
EP 3819007A1 · 2021 [cited by applicant]
EP 3830122A1 · 2021 [cited by applicant]
EP 3912997A2 · 2021 [cited by applicant]
EP 3411402B1 · 2021 [cited by applicant]
EP 3974453A2 · 2022 [cited by applicant]
EP 4039709A1 · 2022 [cited by applicant]
EP 4058148A1 · 2022 [cited by applicant]
EP 4171750A1 · 2023 [cited by applicant]
JP 2001077342A · 2001 [cited by applicant]
JP 2012504403A · 2012 [cited by applicant]
JP 2012521211 · 2013 [cited by applicant]
JP 2013528569A · 2013 [cited by applicant]
JP 2014500879A · 2014 [cited by applicant]
JP 2014515598A · 2014 [cited by applicant]
JP 2014520088A · 2014 [cited by applicant]
JP 2015521032A · 2015 [cited by applicant]
JP 5836927B2 · 2015 [cited by applicant]
JP 2015535002A · 2015 [cited by applicant]
JP 2016500256A · 2016 [cited by applicant]
JP 2016538275A · 2016 [cited by applicant]
JP 6923292B2 · 2021 [cited by applicant]
JP 7030109B2 · 2022 [cited by applicant]
RU 2492186C2 · 2013 [cited by applicant]
RU 2561457C2 · 2015 [cited by applicant]
WO 1996027011A1 · 1996 [cited by applicant]
WO 1996032478A1 · 1996 [cited by applicant]
WO 1997034631A1 · 1997 [cited by applicant]
WO 1998050431A2 · 1998 [cited by applicant]
WO 2000040716A2 · 2000 [cited by applicant]
WO 2001012812A2 · 2001 [cited by applicant]
WO 2001024811A1 · 2001 [cited by applicant]
WO 2001024812A1 · 2001 [cited by applicant]
WO 2001077342A1 · 2001 [cited by applicant]
WO 2001087977A2 · 2001 [cited by applicant]
WO 2002066516A2 · 2002 [cited by applicant]
WO 2004106383A1 · 2004 [cited by applicant]
WO 2005040220A1 · 2005 [cited by applicant]
WO 2005061547A2 · 2005 [cited by applicant]
WO 2006008548A2 · 2006 [cited by applicant]
WO 2007042261A2 · 2007 [cited by applicant]
WO 2007042289A2 · 2007 [cited by applicant]
WO 2007055916A2 · 2007 [cited by applicant]
WO 2007066109A1 · 2007 [cited by applicant]
WO 2007117600A2 · 2007 [cited by applicant]
WO 2007117505A2 · 2007 [cited by applicant]
WO 2008119565A2 · 2008 [cited by applicant]
WO 2008119566A2 · 2008 [cited by applicant]
WO 2008119567A2 · 2008 [cited by applicant]
WO 2008151081A1 · 2008 [cited by applicant]
WO 2009041643A1 · 2009 [cited by applicant]
WO 2009055669A2 · 2009 [cited by applicant]
WO 2009132058A2 · 2009 [cited by applicant]
WO 2010007082A1 · 2010 [cited by applicant]
WO 2010037835A2 · 2010 [cited by applicant]
WO 2010037836A2 · 2010 [cited by applicant]
WO 2010037837A2 · 2010 [cited by applicant]
WO 2010037838A2 · 2010 [cited by applicant]
WO 2010104949A2 · 2010 [cited by applicant]
WO 2010109165A2 · 2010 [cited by applicant]
WO 2011097603A1 · 2011 [cited by applicant]
WO 2012066058A1 · 2012 [cited by applicant]
WO 2012122512A1 · 2012 [cited by applicant]
WO 2012122528A1 · 2012 [cited by applicant]
WO 2012143498A1 · 2012 [cited by applicant]
WO 2012145714A2 · 2012 [cited by applicant]
WO 2012162067A2 · 2012 [cited by applicant]
WO 2012163805A1 · 2012 [cited by applicant]
WO 2013022091A1 · 2013 [cited by applicant]
WO 2013072406A1 · 2013 [cited by applicant]
WO 2013072415A1 · 2013 [cited by applicant]
WO 2013154760A1 · 2013 [cited by applicant]
WO 2014022540A1 · 2014 [cited by applicant]
WO 2014047231A1 · 2014 [cited by applicant]
WO 2014068079A1 · 2014 [cited by applicant]
WO 2014089335A2 · 2014 [cited by applicant]
WO 2014093908A2 · 2014 [cited by applicant]
WO 2014112144A1 · 2014 [cited by applicant]
WO 2014122144A1 · 2014 [cited by applicant]
WO 2014122143A1 · 2014 [cited by applicant]
WO 2014140248A1 · 2014 [cited by applicant]
WO 2015095412A1 · 2015 [cited by applicant]
WO 2015121383A1 · 2015 [cited by applicant]
WO 2015149077A1 · 2015 [cited by applicant]
WO 2016014789A2 · 2016 [cited by applicant]
WO 2016030414A1 · 2016 [cited by applicant]
WO 2016048938A1 · 2016 [cited by applicant]
WO 2016062990A1 · 2016 [cited by applicant]
WO 2016079076A1 · 2016 [cited by applicant]
WO 2016079081A1 · 2016 [cited by applicant]
WO 2016079177A1 · 2016 [cited by applicant]
WO 2016094304A2 · 2016 [cited by applicant]
WO 2016113555A1 · 2016 [cited by applicant]
WO 2019133761A1 · 2016 [cited by applicant]
WO 2016124670A1 · 2016 [cited by applicant]
WO 2016128487A1 · 2016 [cited by applicant]
WO 2016187546A1 · 2016 [cited by applicant]
WO 2017025038A1 · 2017 [cited by applicant]
WO 2017031104A1 · 2017 [cited by applicant]
WO 2017023761A1 · 2017 [cited by applicant]
WO 2017053856A1 · 2017 [cited by applicant]
WO 2015063339A1 · 2017 [cited by applicant]
WO 2017081211A2 · 2017 [cited by applicant]
WO 2017223111A1 · 2017 [cited by applicant]
WO 2018039180A1 · 2018 [cited by applicant]
WO 2018052503A1 · 2018 [cited by applicant]
WO 2018083204A1 · 2018 [cited by applicant]
WO 2018114795A1 · 2018 [cited by applicant]
WO 2018119215A1 · 2018 [cited by applicant]
WO 2018237006A1 · 2018 [cited by applicant]
WO 2018237037A2 · 2018 [cited by applicant]
WO 2018224660A1 · 2018 [cited by applicant]
WO 2019000223A1 · 2019 [cited by applicant]
WO 2019006072A1 · 2019 [cited by applicant]
WO 2019055689A1 · 2019 [cited by applicant]
WO 2019075413A1 · 2019 [cited by applicant]
WO 2019126756A1 · 2019 [cited by applicant]
WO 2019238722A1 · 2019 [cited by applicant]
WO 2020018922A1 · 2020 [cited by applicant]
WO 2020025596A1 · 2020 [cited by applicant]
WO 2020061478A2 · 2020 [cited by applicant]
WO 2020087065A1 · 2020 [cited by applicant]
WO 2020206330A1 · 2020 [cited by applicant]
WO 2020252366A1 · 2020 [cited by applicant]
WO 2021094000A1 · 2021 [cited by applicant]
WO 2021127489A1 · 2021 [cited by applicant]
WO 2021222578A1 · 2021 [cited by applicant]
WO 2021222616A1 · 2021 [cited by applicant]
WO 2021228783A1 · 2021 [cited by applicant]
WO 2022006316A1 · 2022 [cited by applicant]
WO 2022103781A1 · 2022 [cited by applicant]
WO 2022109010A1 · 2022 [cited by applicant]
WO 2022183074A2 · 2022 [cited by applicant]
WO 2022183101A1 · 2022 [cited by applicant]
WO 2022212848A1 · 2022 [cited by applicant]
WO 2022216864A1 · 2022 [cited by applicant]
WO 2022221698A1 · 2022 [cited by applicant]
WO 2022271987A1 · 2022 [cited by applicant]
WO 2023004197A1 · 2023 [cited by applicant]
Salazar-Camarena et al., “Association of BAFF, APRIL Serum Levels, BAFF-R, TACI and BCMA Expression on Peripheral B-cell Subsets with Clinical Manifestations in Systemic Lupus Erythematosus,” (2016) Lupus 25:582-592. [cited by applicant]
Wu et al, “A novel VHH antibody targeting the B cell-activating factor for B-cell lymphoma,” International Journal of Molecular Sciences 15(6):9481-9489. [cited by applicant]
Chinese Excellent Doctoral Dissertation Full-text Database (Electronic Journal Network) Xianchao, “The expression, purification and activity study of APRIL blocking Qi IJ BCMA-Fc,” (2015) Issue 2, E059-37:1-26. [cited by applicant]
Sitia et al., “Developmental Regulation of IgM Secretion: The Role of the Carbosy-terminal Cysteine,” (1990) Cell, 60:781-790. [cited by applicant]
Van der Linden et al., “Comparison of Physical Chemical Properties of Llama VHH Antibody Fragments and Mouse Monoclonal Antibodies,” (1999) Biochimica et Biophysica Acta 1431:37-46. [cited by applicant]
Gust et al., “Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells,” (2017) Cancer Discovery 7(12):1405-1419. [cited by applicant]
Giavridis et al., “CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade,” (2018) Nature Medicine 24:731-738. [cited by applicant]
Anonymous (TeneoBio, Inc.), “A Study of TNB-383B in Subjects with Relapsed or Refractory Multiple Myeloma,” (2019) retrieved from the Internet on May 1, 2019 from URL:https://clinicaltrials.gov/ct2/show/NCT03933735, 4 p… [cited by applicant]
Norelli et al., “Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to Car T cells,” (2018) Nature Medicine24:739-748. [cited by applicant]
Fry et al., “CD22-targeted CAR T Cells Induce Remission in B-ALL that is Naïve or Resistant to CD19-targeted CAR Immunotherapy,” (2018) Nature Medicine 24(1):20-28. [cited by applicant]
Nishimoto et al., “Adoptive Therapy with Cord Blood T Reglatory Cells Enhances Anti-myeloma Efficacy of T Cell Based Immunotherapies,” (2020) Blood 136(Supp1); 26-27. [cited by applicant]
Rodriguez et al., “Initial Resulst of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refracotry Multiple Myeloma,” (2020) Blood 136 (Supp 1):43-44. [cited by applicant]
Rouet et al., “Fully Human VH Single Domains that Rival the Stability and Cleft Recognition of Camelid Antibodies,” (2015) Journal of Biological Chemistry 290(19):11905-11917. [cited by applicant]
Ryan et al., “Antibody Targeting of B-Cell Maturation Antigen on Malignant Plasma Cells,” (2007) Mol Cancer Ther 6(11):3009-3018. [cited by applicant]
Van Schooten et al., “A Novel CD3/BCMA Bispecific Antibody Selectively Kills Plasma Cells in Bone Marrow of Healthy Individuals with Improved Safety,” (2019) Lupus Science and Medicine 6(Supp 1):Abstract 293. [cited by applicant]
Kim et al., “Mutational Approaches to Improve the Biophysical Properties of Human Single-domain Antibodies,” (2014) Biochimica et Biophysica Acta 1844:1983-2001. [cited by applicant]
Hlavacek et al., “Steric Effects on Multivalent Ligand-Receptor Binding: Exclusion of Ligand Sites by Bound Cell Surface Receptors,” (1999) Biophysical Journal 76(6):3031-3043. [cited by applicant]
Plückthun et al., “New protein engineering approaches to multivalent and bispecific antibody fragments,” (1997) Immunology 3(2):83-105. [cited by applicant]
Adams et al., “Prolonged in Vivo Tumour Retention of a Human Diabody Targeting the Extracellular Domain of Human HER2/neu,” (1998) British Journal of Cancer 77(9):1405-1412. [cited by applicant]
Ali et al., “T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma,” (2016) Blood 128(13):1688-1700. [cited by applicant]
Seckinger et al., “Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment,” (2017) Cancer Cell, Cell Press US 31(3):396-410. [cited by applicant]
Anonymous, “Flow Cytometry Antibody: CD3e Cat. No. CT026-R301, SinoBiological Inc,—Antibody-Catalogue,” (2017) Sinobiological, Inc. Retrieved from Internet: URL http://www.sinobiologica.com/flow-cytometry-antibody-elite… [cited by applicant]
Arnett et al., “Crystal Structure of a Human CD3-epsilon/delta Dimer in Complex with a UCHT1 Single-chain Antibody Fragment,” (2004) Proc Natl Acad Sci USA 101(46):16268-16273. [cited by applicant]
Baas et al., “Superhuman Mice,” (2014) Science-Business exchange 7(17):1-2. [cited by applicant]
Borchmann et al., “Phase 1 trial of the Novel Bispecific Molecule H22xKi-4 in Patients with Refractory Hodgkin Lymphoma,” (2002) Blood 100(9):3101-3107. [cited by applicant]
Bruggemann et al., “Heavy-Chain-Only Antibody Expression and B-Cell Development in the Mouse,” (2006) Crit. Rev. Immunol. 26(5):377-390. [cited by applicant]
Buelow et al., “Development of a fully human T cell engaging bispecific antibody for the treatment of multiple myeloma,” (2017) J Clin Oncol vol. 35 Supplement. [cited by applicant]
Carpenter et al., “B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma,” (2013) Clin Cancer Res 19(8):2048-2060. [cited by applicant]
Christian et al., “Measuring Bacterial Ectoenzyme Activities in Marine Waters Using Mercuric Chloride as a Preservative and Control,” (1995) Marine Ecology Progress Series 123:217-224. [cited by applicant]
Dai et al., “Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy,” (2016) J Natl Cancer Inst 108(7):dvj439. [cited by applicant]
Dooley et al., “Selection and Characterization of Naturally Occurring Single-domain (IgNAR) Antibody Fragments from Immunized Sharks by Phage Display,” (2003) Molecular Immunology 40(1):25-33. [cited by applicant]
Desmyter et al., “Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-domain Antibody,” (2001) Journal of Biological Chemistry, American Society for Biochemistry and Molecular Bio… [cited by applicant]
Durben et al., “Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia,” (2015) Molecular Therapy 23(4):648-655. [cited by applicant]
Frenken et al., Isolation of Antigen Specific Llama V [cited by applicant]
Gershoni et al., “Epitope Mapping—The First Step in Developing Epitope-based Vaccines,” (2007) Biodrugs, Adis International, Ltd. NZ 21(3):145-156. [cited by applicant]
Geurts et al., “Knockout Rats via Embryo Microinjection of Zinc-Finger Nucleases,” (2009) Science 325(5939):433. [cited by applicant]
Ghahroudi et al., “Selection and Identification of Single Domain Antibody Fragments from Camel Heavy-chain Antibodies,” (1997) FEBS Lett. 414:521-526. [cited by applicant]
Glennie et al., “Preparation and Performance of Bispecific F(ab′ gamma)2 Antibody Containing Thioether-linked Fab′ gamma Fragments,” (1987) Journal of Immunology 139(7):2367-2375. [cited by applicant]
Ryan et al., “Antibody targeting of B-cell1 maturation antigen on malignant plasma cells,” (2007) Mol Cancer Ther 6(11):3009-3018. [cited by applicant]
Kontermann, “Invited review—Recombinant bispecific antibodies for cancer therapy,” (2005) Acta Pharmacologica Sinica 26(1):1-9. [cited by applicant]
Novak et al., “Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival,” (2004) Blood 103(2):689-694. [cited by applicant]
Sequence Listing of PCT Publication No. WO 2009/132058 (D2), published Oct. 29, 2009. [cited by applicant]
BCMA (Vicky-1): sc-57037 datasheet, Santa Cruz Biotechnology, https://datasheets.scbt.com/sc-57037.pdf (last visited Apr. 12, 2022). [cited by applicant]
BCMA (Vicky-1): ALX-804-151 product datasheet, Enzo Life Sciences, last revised Dec. 20, 2019. [cited by applicant]
MAB193 data sheet, Human BCMA/TNFRSF17 Antibody, R&D Systems, last revised Feb. 7, 2018. [cited by applicant]
Hipp et al., “A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo,” (2017) Leukemia 31:1743-1751. [cited by applicant]
Sequence Listing of PCT Publication WO 2008/119567 (D14), published Oct. 9, 2008. [cited by applicant]
GenBank Accession No. AB052772.1, “ [cited by applicant]
Sequence listing of PCT Publication No. WO 2010/104949 (D21), published Sep. 16, 2010. [cited by applicant]
Fitzgerald et al., “The Cytokine FactsBook,” 2nd ed. (2001) Academic Press, pp. 151-152. [cited by applicant]
Bossen et al., “Review, BAFF, APRIL and their receptors: Structure, function and signaling,” (2006) Seminars in Immunology 18:263-275. [cited by applicant]
Bodmer et al., “Review—The molecular architecture of the TNF superfamily,” (2002) Trends in Biochemical Sciences 27(1):19-26. [cited by applicant]
Hymowitz et al., “Structures of APRIL-Receptor Complexes,” (2005) Journal of Biological Chemistry 280(8):7218-7227. [cited by applicant]
Liu et al., “Ligand-receptor binding revealed by the TNF family member TALL-1,” (2003) Nature 423:49-56. [cited by applicant]
Wallweber et al., “The Crystal Structure of A Proliferation-inducing Ligand, APRIL,” (2004) Journal of Molecular Biology 343:283-290. [cited by applicant]
Patel et al., “Engineering an APRIL-specific B Cell Maturation Antigen,” (2004) Journal of Biological Chemistry 279(16):16727-16735. [cited by applicant]
Vidal-Laliena et al., “Characterization of antibodies submitted to the B cell section of the 8th human leukocyte differentiation antigens workshop by flow cytometry and immunohistochemistry,” (2005) Cellular Immunology … [cited by applicant]
Moreaux et al., “APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop,” (2009) Eur J Heamatol 83:119-129. [cited by applicant]
Bellucci et al., “Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor,” (2005) Blood 105(10):3945-3950. [cited by applicant]
Bellucci et al., “Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens,” (2004) Blood 103(2):656-663. [cited by applicant]
Leiba et al., “Activation of B cell maturation antigen (BCMA) on human multiple myeloma cells by a proliferation-inducing ligand (APRIL) promotes myeloma cell function in the bone marrow microenvironment,” (2007) Blood … [cited by applicant]
Bellucci et al., “Complete response to donor lymphocyte infusion in patients with multiple myeloma is associated with antibody response to BCMA, a plasma cell membrane receptor,” (2003) Blood 102(11):192a-193a. [cited by applicant]
Tarte et al., “BAFF is a survival factor for multiple myeloma cells,” (2002) Myeloma Biology II, p. 811a (Abstract #3203). [cited by applicant]
Dillon et al., “An APRIL to remember: Novel TNF ligands as therapeutic targets,” (2006) Nat Rev 5:235-246. [cited by applicant]
Kontermann “Bispecific Antibodies” (2011) Springer-Verlag Berlin Heidelberg, Chapters 1, 2, 7, 11, 13, 14 and 15. [cited by applicant]
Choi et al., “Bispecific antibodies engage T-cells for antitumor Immunotherapy,” (2011) Expert Opinion on Biological Therapy 11(7):843-853. [cited by applicant]
Müller et al., “Bispecific antibodies for cancer immunotherapy,” (2010) Biodrugs 24(2):89-98. [cited by applicant]
Thakur et al., “Cancer therapy with bispecific antibodies: Clinical experience,” (2010) Current Opinion in Molecular Therapeutics 12(3):340-349. [cited by applicant]
Chames et al., “Bispecific antibodies for cancer therapy,” (2009) Current Opinion in Drug Discovery & Development 12(2):276-283. [cited by applicant]
Baeuerle et al., “Bispecific T-cell engaging antibodies for cancer therapy,” (2009) Cancer Research 69(12):4941-4944. [cited by applicant]
Baeuerle et al., “BiTE: Teaching antibodies to engage T-cells for cancer therapy,” (2009) Current Opinion in Molecular Therapeutics 11(1):22-30. [cited by applicant]
Baeuerle et al., “BiTE: A new class of antibodies that recruit T-cells,” (2008) Drugs of the Future 33(2):137-147. [cited by applicant]
Muller et al., “Recombinant bispecific antibodies for cellular cancer immunotherapy,” (2006) Current Opinion in Molecular Therapeutics 9(4):319-326. [cited by applicant]
Kufer et al., “Review—A revival of bispecific antibodies,” (2004) Trends in Biotechnology 22(5):238-244. [cited by applicant]